Unilife Corp

Unilife — Q3 FY2011 Earnings Presentation

13 slides from Unilife's earnings presentation, May 16, 2011

  1. Slide 1: Fiscal 2011 3rd Quarter Conference Call

    Fiscal 2011 3rd Quarter Conference Call May 16, 2011

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    2 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward- looking statements are based on management's beliefs and assumptions and on information currently available to our m

  3. Slide 3: Recent Highlights

    3 Recent Highlights Began initial production of Unifill ready-to-fill (prefilled) syringe Final product validation procedures now underway Unifill sales to commence during July 2011 Realignment to drive business growth, accelerate new product development and streamline costs Strengthened frontline t

  4. Slide 4: Q3 2011 Financial Data

    4 Richard Wieland Chief Financial Officer Q3 2011 Financial Data

  5. Slide 5: Financial Data - Fiscal 3rd Quarter 2011

    5 Financial Data - Fiscal 3rd Quarter 2011 Revenues for the quarter of $0.7m, compared to $2.4m for 3Q 2010 Unifill industrialization revenue decreased by $1.2m from 3Q 2010 Net loss for the quarter was $(12.5)m, or $(0.20) per diluted share, compared to $(12.1)m, or $(0.23) per diluted share, for 3

  6. Slide 6: Financial Data - Fiscal 3rd Quarter 2011 (cont.)

    Financial Data - Fiscal 3rd Quarter 2011 (cont.) Balance Sheet Data (As of March 31, 2011) Cash, restricted cash and cash equivalents of $30.2m Equipment Financing (anticipated to close in June 2011) Signed term sheet for $12.0m line of equipment financing Will utilize $12.7m for Unifill production

  7. Slide 7: Q3 2011 Overview

    7 Q3 2011 Overview Alan Shortall Chief Executive Officer

  8. Slide 8: Unifill Ready-to-Fill Syringes

    8 Initial production commenced on schedule in March 2011 Final product validation underway Sales to commence in July 2011 Marks successful completion of industrialization program Discussions at various stages with multiple pharma companies Initial sales used for market evaluation, stability studies

  9. Slide 9: Increased Demand for Customized Devices

    9 Pharmaceutical and biotech companies increasingly seeking customized drug delivery device solutions for targeted pipeline drugs Drug R&D shifting to specialized injectables (high-molecule biologics) Devices being customized to meet specific drug / patient needs Trend is to outsource device develop

  10. Slide 10: Building a Broad Proprietary Device Portfolio

    Building a Broad Proprietary Device Portfolio 10

  11. Slide 11: Operational Realignment

    Operational Realignment Scheduled business realignment initiated in March 2011 Eliminated legacy positions once surge for Unifill completed Strengthened commercial sales and marketing team Dynamic cross-functional teams to drive new device projects Benefits of realignment include: Expanded commercia

  12. Slide 12: Expanding the Size and Scope of Unilife

    Expanding the Size and Scope of Unilife Unilife is much more than just a safety syringe company Ready to serve as preferred partner for device innovation Unifill syringe a gateway enabling Unilife to enter other high-value markets for advanced drug delivery systems Achieved what others thought impos

  13. Slide 13: Questions

    Fr uniuice®? Questions

Unilife — Q3 FY2011 Earnings Presentation on 6ix